What's Going On With Merck Shares Wednesday?
What's Going On With Merck Shares Wednesday?
"We continue to leverage science-driven business development to augment and complement our robust pipeline," said Merck & Company Inc (NYSE:MRK) on Wednesday announced a GLP-1 agreement with Chinese biopharmaceutical company Hansoh Pharma.
默沙東公司（紐交所代碼：MRK）週三宣佈與中國生物製藥公司翰森製藥達成GLP-1協議。
What Happened: Merck and Hansoh entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
發生了什麼：默沙東與翰森製藥簽訂了HS-10535的獨家全球許可協議，這是一種正在研究中的口服小分子GLP-1受體激動劑。
Hansoh Pharma granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. The Chinese biopharmaceutical company will receive an upfront payment of $112 million and up to $1.9 billion in milestone payments. Hansoh will also receive royalties on sales.
翰森製藥授予默沙東獨家全球許可，開發、生產和商業化HS-10535。這家中國生物製藥公司將獲得$11200萬的預付款以及高達$19億的里程碑付款。翰森還將從銷售中獲得版稅。
"We continue to leverage science-driven business development to augment and complement our robust pipeline," said Dean Li, president of Merck Research Laboratories.
默沙東研究實驗室主席Dean Li表示：「我們繼續利用以科學驅動的業務開發來增強和補充我們強大的產品管線。」
"Through this agreement, we aim to build on our experience targeting incretin biology to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction."
他補充道：「通過此次協議，我們旨在充分利用我們在靶向腸促胰素生物學方面的經驗，評估HS-10535及其在減重之外提供額外心代謝益處的潛力。」
As a result of the agreement, Merck said it expects to record a fourth-quarter pre-tax charge of $112 million, or 4 cents per share.
由於該協議，默沙東表示預計將記錄一項四季度的稅前費用爲$11200萬，或每股4美分。
Merck is not due to report its fourth-quarter financial results until February. Analysts currently expect the company to report earnings of $1.83 per share and revenue of $15.43 billion, according to estimates from Benzinga Pro.
默沙東直到2月份才會公佈其四季度財務結果。分析師預計該公司每股收益爲$1.83，營業收入爲$154.3億，根據Benzinga Pro的估計。
MRK Price Action: Merck shares were up 0.83% at $100.89 at the time of writing Wednesday, according to Benzinga Pro.
MRK價格表現：根據Benzinga Pro的數據，撰寫時默沙東的股價上漲了0.83%，達到了$100.89。
Photo: courtesy of Merck.
照片：來自默沙東。
譯文內容由第三人軟體翻譯。
